Jacome Sanz, D.; Raivola, J.; Karvonen, H.; Arjama, M.; Barker, H.; Murumägi, A.; Ungureanu, D.
Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. Cancers 2021, 13, 3727.
https://doi.org/10.3390/cancers13153727
AMA Style
Jacome Sanz D, Raivola J, Karvonen H, Arjama M, Barker H, Murumägi A, Ungureanu D.
Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. Cancers. 2021; 13(15):3727.
https://doi.org/10.3390/cancers13153727
Chicago/Turabian Style
Jacome Sanz, Dafne, Juuli Raivola, Hanna Karvonen, Mariliina Arjama, Harlan Barker, Astrid Murumägi, and Daniela Ungureanu.
2021. "Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors" Cancers 13, no. 15: 3727.
https://doi.org/10.3390/cancers13153727
APA Style
Jacome Sanz, D., Raivola, J., Karvonen, H., Arjama, M., Barker, H., Murumägi, A., & Ungureanu, D.
(2021). Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. Cancers, 13(15), 3727.
https://doi.org/10.3390/cancers13153727